JAHA:急性心梗伴肝硬化患者的β受体阻滞剂该如何选择?

2018-09-30 MedSci MedSci原创

目前,β1选择性抑制剂或非选择性β抑制剂对于肝硬化伴急性心梗的患者是否有效尚不清楚。本研究纳入了台湾NHIRD数据库中的患者,并比较了服用β1选择性抑制剂治疗和非选择性β抑制剂患者的预后,主要终点事件是1年和2年的心血管事件、肝脏不良事件和全因死亡率。最终共纳入了203595名急性心梗患者,其中6355名伴有肝硬化。经过排除标准后,共分析了1769名患者(655名接受β受体阻滞剂治疗,1114名没

目前,β1选择性抑制剂或非选择性β抑制剂对于肝硬化伴急性心梗的患者是否有效尚不清楚。

本研究纳入了台湾NHIRD数据库中的患者,并比较了服用β1选择性抑制剂治疗和非选择性β抑制剂患者的预后,主要终点事件是1年和2年的血管事件、肝脏不良事件和全因死亡率。最终共纳入了203595名急性心梗患者,其中6355名伴有肝硬化。经过排除标准后,共分析了1769名患者(655名接受β受体阻滞剂治疗,1114名没接受β受体阻滞剂治疗)。在接受β受体阻滞剂治疗的患者中,根据倾向性评分,分析比较了218名β1选择性抑制剂患者和218名非选择性β抑制剂患者,经过2年时间的随访,接受β1选择性抑制剂治疗的患者发生主要不良心脑血管事件的风险更低(HR:0.62; 95% Cll=0.42‐0.91;P=0.014),全因死亡率的趋势也更低,肝脏不良事件无明显差异。

研究结果显示,对于急性心梗伴肝硬化的患者,β1选择性抑制剂在β受体阻滞剂中可能是个更好的选择。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085805, encodeId=28ee20858052d, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Oct 09 16:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995187, encodeId=b8e0199518e63, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jul 25 14:43:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267938, encodeId=fed3126e93890, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274972, encodeId=511012e4972ac, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308378, encodeId=ebe013083e8c3, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046344, encodeId=41cc1046344e6, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Sep 30 23:43:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-10-09 zhyy88
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085805, encodeId=28ee20858052d, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Oct 09 16:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995187, encodeId=b8e0199518e63, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jul 25 14:43:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267938, encodeId=fed3126e93890, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274972, encodeId=511012e4972ac, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308378, encodeId=ebe013083e8c3, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046344, encodeId=41cc1046344e6, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Sep 30 23:43:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085805, encodeId=28ee20858052d, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Oct 09 16:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995187, encodeId=b8e0199518e63, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jul 25 14:43:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267938, encodeId=fed3126e93890, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274972, encodeId=511012e4972ac, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308378, encodeId=ebe013083e8c3, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046344, encodeId=41cc1046344e6, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Sep 30 23:43:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-10-02 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085805, encodeId=28ee20858052d, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Oct 09 16:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995187, encodeId=b8e0199518e63, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jul 25 14:43:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267938, encodeId=fed3126e93890, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274972, encodeId=511012e4972ac, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308378, encodeId=ebe013083e8c3, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046344, encodeId=41cc1046344e6, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Sep 30 23:43:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2085805, encodeId=28ee20858052d, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Oct 09 16:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995187, encodeId=b8e0199518e63, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jul 25 14:43:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267938, encodeId=fed3126e93890, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274972, encodeId=511012e4972ac, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308378, encodeId=ebe013083e8c3, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046344, encodeId=41cc1046344e6, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Sep 30 23:43:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2085805, encodeId=28ee20858052d, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Oct 09 16:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995187, encodeId=b8e0199518e63, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jul 25 14:43:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267938, encodeId=fed3126e93890, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274972, encodeId=511012e4972ac, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308378, encodeId=ebe013083e8c3, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Oct 02 11:43:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046344, encodeId=41cc1046344e6, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Sep 30 23:43:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-09-30 guging

    谢谢!最新的信息读起来就是收获大

    0

相关资讯

JAHA:前列腺素受体2在受损心脏修复中起重要作用

前列腺素E2是公认的免疫调节因子,它在组织受损后释放,并参与调控巨噬细胞的活性,然而前列腺素受体2(EP2)调节的巨噬细胞在心脏缺血后的作用尚不清楚。本研究的目的旨在探究EP2在受损心脏中的作用。本研究利用EP2转基因小鼠模型,发现EP2敲除小鼠的心脏在受损后心功能会更差,并且EP2的缺失会改变促炎反应,导致巨噬细胞聚集于受损心肌的缺陷。转录组分析结果显示红系分化调节蛋白1(Erdr1)在EP2敲

JAHA:心血管危险因素对女性冠心病和卒中的影响

心血管危险因素对心血管疾病的各种表现有不同的影响,但到目前为止,直接进行比较较少见,且主要在男性中比较。本研究纳入比较了1731名心血管疾病的女性与1914名正常的女性,发现24大危险因素(包括各种载脂蛋白、血红蛋白A1C、高灵敏度C反应蛋白、N末端脑钠肽和组织纤溶酶原激活物抗原)的作用方向在冠心病(CHD)和缺血性卒中中是一致的,但在CHD中相关性更强。当比较出血性脑卒中与缺血性脑卒中的疗效时,

JAHA:他汀类药物可改善腹主动脉瘤患者预后

目前,腹主动脉瘤(AAA)没有特效的药物治疗,尽管有研究显示他汀类药物对AAA有益处。本荟萃分析的目的旨在评估他汀类药物对AAA的生长、破裂和30天死亡率的影响。本次荟萃分析纳入分析了911篇临床文章,包括1个病例对照研究和21个队列研究,共计80428例患者。分析结果显示,他汀类药物的使用与AAA生长率减少0.82 mm/y呈相关性(95% Cl 0.33- 1.32,P=0.001, I2=8

JACC:血栓抽吸不能改善高血栓风险STEMI患者预后

常规的血栓抽吸对接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者来说并不会改善预后,但对有高血栓风险的该类患者来说是否有益尚不清楚。本研究的目的旨在评估血栓抽吸对伴高血栓风险的STEMI患者是否有益。本研究纳入的是TOTAL临床研究中的STEMI患者,主要终点事件是心源性死亡、心梗、心源性休克和心衰。分析结果显示,1年主要终点事件在接受血栓抽吸的高血栓风险STEMI患者和不接受抽

JACC:二尖瓣环分离心律失常综合征

二尖瓣环分离(MAD)会引起二尖瓣脱垂(MVP)和心源性猝死。本研究的目的旨在评估MAD患者的临床特征、二尖瓣形态、MVP情况及室性心律失常情况。本研究最终纳入了116名MAD患者(平均年龄49±15岁,女性占60%)。心悸是最常见的临床症状(71%),严重的心律不齐占14例(12%)。伴心律不齐的MAD患者年龄更小(p = 0.001),射血分数更低(51 ± 5% vs. 57 ± 7%; p

JACC:多摄入海产品可降低外周动脉疾病风险

动物脂肪组织的海洋n-3多不饱和脂肪酸(PUFAs)含量被认为是机体长期摄入海产品的生物标志物。本研究的目的旨在评估机体脂肪组织中PUFAs的含量与外周动脉疾病(PAD)的关系。本研究纳入了丹麦饮食、癌症和健康研究队列中的对象,脂肪组织是从所有研究对象的臀部获取,经过平均13.5年时间的随访,共有870例对象出现PAD。分析结果显示,二十碳五稀酸(EPA)含量越高,PAD的发生风险越低([HR]: